| Next generation of immune checkpoint therapy in cancer: new developments and challenges JA Marin-Acevedo, B Dholaria, AE Soyano, KL Knutson, S Chumsri, ... Journal of hematology & oncology 11, 1-20, 2018 | 833 | 2018 |
| Cancer immunotherapy beyond immune checkpoint inhibitors JA Marin-Acevedo, AE Soyano, B Dholaria, KL Knutson, Y Lou Journal of hematology & oncology 11, 1-25, 2018 | 232 | 2018 |
| Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma JM Logue, E Zucchetti, CA Bachmeier, GS Krivenko, V Larson, D Ninh, ... Haematologica 106 (4), 978, 2020 | 225 | 2020 |
| Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... Journal of Clinical Oncology 40 (25), 2901-2912, 2022 | 213 | 2022 |
| NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JE Chang, B Christian, JS Abramson, RH Advani, ... Journal of the National Comprehensive Cancer Network 19 (11), 1218-1230, 2021 | 140 | 2021 |
| Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies AE Soyano, B Dholaria, JA Marin-Acevedo, N Diehl, D Hodge, Y Luo, ... Journal for immunotherapy of cancer 6, 1-9, 2018 | 126 | 2018 |
| Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation … MA Kharfan-Dabaja, A Kumar, E Ayala, M Aljurf, T Nishihori, R Marsh, ... Transplantation and cellular therapy 27 (8), 642-649, 2021 | 115 | 2021 |
| Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice S Sengsayadeth, BN Savani, O Oluwole, B Dholaria EJHaem 3, 6-10, 2022 | 111 | 2022 |
| Emerging therapeutic agents for lung cancer B Dholaria, W Hammond, A Shreders, Y Lou Journal of Hematology & Oncology 9, 1-14, 2016 | 104 | 2016 |
| CAR T cell therapy in solid tumors: A review of current clinical trials U Patel, J Abernathy, BN Savani, O Oluwole, S Sengsayadeth, B Dholaria EJHaem 3, 24-31, 2022 | 102 | 2022 |
| Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities BR Dholaria, CA Bachmeier, F Locke BioDrugs 33 (1), 45-60, 2019 | 95 | 2019 |
| Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... The Lancet Haematology 10 (11), e890-e901, 2023 | 83 | 2023 |
| Chimeric antigen receptor T cell therapy during the COVID-19 pandemic V Bachanova, MR Bishop, P Dahi, B Dholaria, SA Grupp, B Hayes-Lattin, ... Biology of Blood and Marrow Transplantation 26 (7), 1239-1246, 2020 | 81 | 2020 |
| Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT B Dholaria, BN Savani, M Labopin, L Luznik, A Ruggeri, S Mielke, ... haematologica 105 (1), 47, 2019 | 74 | 2019 |
| Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas PA Riedell, WT Hwang, LJ Nastoupil, M Pennisi, JP McGuirk, RT Maziarz, ... Transplantation and cellular therapy 28 (10), 669-676, 2022 | 70 | 2022 |
| Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and … B Dholaria, BN Savani, BK Hamilton, B Oran, HD Liu, MS Tallman, ... Transplantation and Cellular Therapy 27 (1), 6-20, 2021 | 70 | 2021 |
| Spicy seizure S Pant, B Dholaria, V Kaur, S Ramavaram, M Ukor, A Deshmukh, ... The American journal of the medical sciences 344 (1), 67-68, 2012 | 69 | 2012 |
| Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial NJ Bahlis, CL Costello, NS Raje, MY Levy, B Dholaria, M Solh, ... Nature medicine 29 (10), 2570-2576, 2023 | 67 | 2023 |
| Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma J Zurko, J Ramdial, M Shadman, S Ahmed, A Szabo, L Iovino, AA Tomas, ... Haematologica 108 (1), 98, 2022 | 61 | 2022 |
| Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant M Scordo, TP Wang, KW Ahn, Y Chen, S Ahmed, FT Awan, A Beitinjaneh, ... JAMA oncology 7 (7), 993-1003, 2021 | 60 | 2021 |
